StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

Investment analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a report issued on Monday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOLASE Price Performance

BIOL opened at $0.01 on Monday. The business has a fifty day simple moving average of $0.01 and a 200-day simple moving average of $0.02. The firm has a market cap of $309,014.75, a PE ratio of 0.00 and a beta of 0.67. BIOLASE has a fifty-two week low of $0.02 and a fifty-two week high of $1.94.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.